Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biotech CEO: Bayh-Dole 'fix' won't lower drug prices

By: via Business Journals
A proposal to amend Bayh-Dole won’t, in fact, have the intended impact of reducing drug prices, writes John Glasspool, CEO of Anthos Therapeutics Inc. in Cambridge.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.